Drug Trial Radar · NCT04472728
Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
238
Actual
Start
Aug 26, 2020
Primary completion
Jun 6, 2022
Study completion Jun 6, 2022
Sponsor
- Lead sponsor
- BiophytisIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in participants with SARS-CoV-2 pneumonia. Part 1 is a Phase 2 exploratory Proof of Concept (PoC) study to provide preliminary data on the activity, safety and tolerability of BIO101 in the target population. Part 2 is a phase 3 pivotal randomized study to provide further evidence of safety and efficacy of BIO101 after 28 days of double-blind dosing. BIO101 is the investigational new drug that activates the Mas receptor (MasR) through the protective arm of the Renin Angiotensin System (RAS).
Conditions
- Covid-19
- SARS-CoV2
Interventions
BIO101Drug
BIO101 capsules
PlaceboDrug
placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Negative EventsTime frame: Up to 28 days
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
Abrazo Health
Phoenix, Arizona
University of California, Irvine
Irvine, California
Barnum Medical Research, Inc. 1029 Keyser Ave Suite H
Natchitoches, Louisiana
Beaumont Health
Royal Oak, Michigan
United Health Services Hospitals
Johnson City, New York
WellSpan Health
York, Pennsylvania
CHU Saint-Pierre
Brussels, Belgium
AZ-Sint Maarten
Mechelen, Belgium
CHU CLU Namur (Saint-Elisabeth) Place Louise Godin
Namur, Belgium
Avenida Dr. Enéas de Carvalho Aguiar, 44 - Centro de Pesquisa Clínica Prof. Dr. Fúlvio Pileggi - Bloco 1 - 1º Andar
São Paulo, Brazil
Hospital Vera Cruz
Belo Horizonte, Minas Gerais, Brazil
Santa Casa de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Municipal de Barueri Dr. Francisco Moran
Barueri, São Paulo, Brazil
Hospital e Maternidade Celso Pierro - PUCCAMP
Campinas, São Paulo, Brazil
Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Centre Hospitalier Argenteuil
Argenteuil, France
Centre Hospitalier Universitaire Bordeaux
Bordeaux, France
Centre Hospitalier Rene Dubos
Cergy-Pontoise, France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France
Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris
Paris, France
Unité ambulatoire Service de Pneumologie, Médecine Intensive et Réanimation (SPMIR) 47-83 Boulevard de l'Hôpital
Paris, Paris Cedex 13, France
FDI Clinical Research - San Juan City Hospital
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.